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Abstract
An ongoing interest in innovation studies is to understand how knowledge generated from scientific
research can be used in the development of technologies. While previous inquiries have devoted
to studying the scientific capacity of technologies and institutional factors facilitating technology
transfer, little is known about the intrinsic characteristics of scientific publications that gain direct
technological impact. Here we focus on two features, namely basicness and novelty. Using a corpus
of 3.8 million papers published between 1980 and 1999, we find that basic science papers and novel
papers are substantially more likely to achieve direct technological impact. Further analysis that
limits to papers with technological impact reveals that basic science and novel science have more
patent citations, experience shorter time lag, and have impact in broader technological fields.
Keywords: patent-to-paper citation, non-patent reference, technological impact, basic research,
novelty
1. Introduction
It has been long argued and empirically demonstrated that scientific research spurs technological
innovation, promotes economic growth, and improves human health. One line of inquiry has em-
phasized establishing the intimate interplay between science and technology (Breschi and Catalini,
2010; Cockburn and Henderson, 1996; Godin, 1996; Han and Magee, 2018; Jaffe, 1989; McMillan
et al., 2000; Meyer, 2001; Narin et al., 1997). An early study by Jaffe (1989), for example, found
a significant spillover effect of university research on corporate patents. Another stream of works
from a range of fields has provided abundant evidence on the effects of publicly funded biomedical
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research on the improvement of health outcomes (Blume-Kohout, 2012; Cockburn and Henderson,
1996; Comroe and Dripps, 1976; Cutler and Kadiyala, 2003; Manton et al., 2009; Morlacchi and
Nelson, 2011; Sampat and Lichtenberg, 2011; Stevens et al., 2011). Focusing on cardiovascular
disease as a case study, Cutler and Kadiyala (2003) estimated a 4-to-1 return for investments in
new treatments and 30-to-1 return for investments in health knowledge. These lines of researches
together substantiate the effects of scientific research, providing basis for the advocation of public
support for science.
Accompanying ample studies of the effects of scientific research is the understanding of the
mechanisms and channels through which such effects are realized. Among the diverse channels, a
widely recognized one is new technologies, and revealing how knowledge produced from scientific
research can be used in the development of technologies is an important topic in the innovation
study literature. Prior literature on this topic has suggested numerous institutional factors that may
facilitate the science-to-technology translation process, from the perspectives of both the university
side (Debackere and Veugelers, 2005; Etzkowitz and Leydesdorff, 2000; Gregorio and Shane, 2003)
and the private sector side (Cockburn and Henderson, 1996; Gambardella, 1992; Laursen and Salter,
2006).
A less explored perspective, which is the focus of this work, is science itself. Here we ask: Which
characteristics of scientific publications make them more likely to be cited in front-pages of patented
technologies (also known as “prior art”)? We are primarily interested in two features, namely basic
science and novel science.
Our interest in basic science comes from its role as “the pacemaker of technological progress.” In
a 1945 report to the President of the United States of America titled Science: The Endless Frontier
(Bush, 1945), Vannevar Bush made a distinction between basic and applied research and claimed
an essential role of basic science in technological innovation and economic growth. He argued that,
in order to promote growth, it is government’s concern to support and sustain basic research. In
our focused area of biomedical research, numerous studies have established that basic science lays
the foundations for therapeutic applications that improve human health (Comroe and Dripps, 1976;
Cutler and Kadiyala, 2003; Stevens et al., 2011). In this work, we add to another dimension of
the impact of basic science by empirically investigating whether it is more likely to attain direct
technological impact, as defined as being referenced as “prior art” by patented technologies.
Novelty is the other feature studied in this work because of its particularity of high risk and high
2
return. Novel science, when combined with high conventionality, has been shown to exhibit partic-
ular advantage to be scientific breakthroughs (Uzzi et al., 2013), but at the same time encounters
resistance of acceptance from existing paradigms and thus experiences delay recognition from the
scientific community. In biomedical research, it has been reported that researchers tend to adopt
conservative approaches (Rzhetsky et al., 2015), and funding agencies tend to favor safe project
proposals rather than novel and risk ones that explore uncharted areas, although funding policy is
one of the key drivers of scientific creativity (Azoulay et al., 2011). Here we ask: Is novel science
more likely to generate technological impact? Does novel science also face delayed recognition in
the technology sphere like in the scientific community?
To answer these questions, we draw on two large-scale corpora: (1) 3.8 million papers published
between 1980 and 1999 and indexed in the MEDLINE database, and (2) all utility patents granted
at the U.S. Patent and Trademark Office (USPTO) until 2012. We show that basic science papers
are more likely to achieve technological impact than comparable clinical research papers in the
same field and the same year, and the effect size is large. This positive linkage to technological
impact also holds for novel science. We further find that both positive linkages are robust even
after controlling for a range of confounders like the quality of papers and journal Impact Factor,
and consistent during the studied 20-year period. Additional analysis on the subset of papers that
are cited by patents reveals that basic science and novel science have more patent citations and a
broader scope of technological impact. Moreover, it takes less time for both of them to have impact
in the technology space.
2. Literature review
2.1. Technological impact of scientific research
Tracing and understanding how scientific research contribute to the development of technologies
has been an important question in the literature of innovation studies. Following the seminal work
of Narin et al. (1997), empirical measurement of science-technology interaction has largely relied
on non-patent references (NPR) that are listed in the front-pages of patents and refer to scientific
publications. Hereafter, we call those references scientific NPRs, or SNPRs. They are, however,
not the only type of data used for studying the interaction. Some existing works, for example, have
used references in the full-text of patents (Bryan et al., 2019), or have employed natural language
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processing techniques to understand text of scientific papers and patents (Xu et al., 2019). In this
work, we follow the literature that uses front-page SNPRs.
What do SNPRs represent? How can one interpret them? These questions are still in discussion.
One of the most popular interpretations is that SNPRs signal knowledge flow from science to
technology. Narin et al. (1997) observed a rapid increase of the volume of citations from U.S. patents
to public science, defined as research conducted at universities and public research organizations,
and argued that there was a growing reliance of technologies on public science. In the follow-up
work, McMillan et al. (2000) examined SNPRs in patents from the biotechnology industry and
found that its reliance on public science is more evident than other industries.
A limited number of studies instead set out to examine the validity of representing SNPRs
as knowledge flows. Meyer (2000) studied front-page SNPRs of several patents about nanoscale
technologies and suggested that the interpretation of a direct knowledge link from cited papers
to citing patents is hardly guaranteed and scientific papers play an indirect role by providing
background information. Callaert et al. (2014) conducted interviews with inventors at Belgian
firms and institutes and reported two observations: (1) 30% of patents with scientific knowledge
as a source of inspiration do not have any SNPRs; (2) half of SNPRs served as unimportant or
background information. They suggested that the knowledge flow interpretation is not guaranteed
and SNPRs may also signal relatedness (e.g., providing background information) between citing
patent and cited paper. Roach and Cohen (2013) termed the first observation as “errors of omission”
and examined another type of distortion called “errors of commission”—citations that contributed
to the invention were not reported. They used the Carnegie Mellon Survey of the Nature and
Determinants of Industrial R&D where lab managers reported how knowledge originated from
public research organizations was used in R&D. Their analysis suggested that citations to scientific
publications more align with reports from managers than citations to patents; that is, compared
with representing backward patent citations as knowledge flow, SNPRs better represent this notion.
Regardless of the extent of the validity of the knowledge flow interpretation, SNPRs provide
a valuable lens through which one can understand the linkage from science to technology. Many
studies towards this goal take the patent-centric perspective. Fleming and Sorenson (2004) pro-
posed a mechanism through which science can contribute to technology is that science alters the
combinatorial search process towards more useful combinations and corroborated the mechanism
with empirical analysis showing that patents referencing science get more forward patent citations.
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Cassiman et al. (2008) found that patents that have SNPRs have a broader scope of citations re-
ceived from patents. In a large-scale study consisting of 22.9 million MEDLINE papers and 4.8
million U.S. patents, Ke (2019a) observed an exponential growth of SNPRs, doubling every 2.9
years over a 23-year period (1976–1998).
The time dimension of technological impact is another topic of interest. Using a sample of
U.S. patents from 1975 to 1989, Narin and Olivastro (1992) presented a retrospective analysis of
patent-to-paper citation linkage, finding that electronics and pharmaceuticals patents tend to cite
more recent papers, with a median lag of 3–4 years. Ke (2018) instead analyzed the time facet in
a prospective manner and found that, for the majority of biomedical papers, their citations from
patents lag behind citations from scientific papers and the median lag is 6 years.
Previous studies have also observed homophily in patent-to-paper citation linkage with respect
to the field and country dimension. Narin et al. (1997), for example, observed an apparent subject-
specific linkage to science; that is, drug and medicine patents mostly cite clinical medicine and
biomedical research papers, and chemical patents cite chemistry papers. A similar observation is
noted in Meyer (2001). In terms of the country aspect, Narin et al. (1997) found that patents
originated from one country tend to cite papers authored from the same country.
What remains relatively less studied is from the paper -centric perspective. What are the char-
acteristics of scientific papers that accrue technological impact? Ahmadpoor and Jones (2017)
presented an analysis of an integrated network formed by patent-to-patent, patent-to-paper, and
paper-to-paper citations. They found that papers that are directly cited by patents are from fields
like nanoscience and nanotechnology, computer science, etc. Mathematics papers, on the other
hand, are distant to the technological space, meaning that several intermediate papers are needed
in order to form a citation path from a patent to a mathematics paper. Ke (2018) found that
only 4% of papers are directly cited by patents. Yet, the fraction varies by field; biotechnology,
virology, biochemistry, molecular biology, allergy and immunology, and cell biology have more than
10%, whereas medicine and general surgery have less than 2%. Another studied characteristic is
the novelty of papers. Using papers published in 2001, Veugelers and Wang (2019) found that
within-filed novel papers are more likely to have patent citations.
While features examined in the above studies are of ex ante, other prior works have instead
investigated ex post features, among which scientific impact is perhaps the one received the most
attention. Studies have repeatedly established an overall positive association between scientific
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impact and technological impact; that is, the number of citations received by a paper from other
scientific papers and from patents are positively correlated (Ahmadpoor and Jones, 2017; Ke, 2018;
Popp, 2017). However, Ke (2018) further noted that within biomedicine, there is a low similarity
between the set of top papers based on scientific impact and that based on the technological impact.
2.2. Basic research and technological impact
In this work, we are interested in the biomedicine area and aim to understand technological
impact of biomedical research in terms of the paper-centric perspective. We study two kinds of
paper characteristics—basicness and novelty—that are highly relevant to the current science policy
discussions. We hypothesize that both of them may link to technological impact.
Our interest in basic science resides in its long-argued spillover effect in driving applied research
and innovations. Bush (1945) argued that new knowledge generated from basic research is essential
to technological and economic development and it is of government’s concern to support and sustain
basic research in order to promote such development. These arguments have later been absorbed
into the widely discussed (and criticized) “linear model” of innovation (Balconi et al., 2010). Em-
pirically, Narin et al. (1976) developed an indicator that categorized papers into four groups (basic
research, clinical investigation, clinical mix, and clinical observation) based on journals where they
were published. In their later work, Narin et al. (1997) found that most papers that are cited by
patents are from the basic research category. Using an indicator that quantifies the extent to which
a biomedical paper is basic science or clinical medicine (Ke, 2019b), Ke (2019a) similarly found that
patent-referenced papers are overwhelmingly from the basic science end of the basic-clinical spec-
trum. But for the subset of patents that are related to the development of FDA-approved drugs,
a significant portion of their cited papers are located at the clinical research end of the spectrum
(Ke, 2019a).
In light of these studies, our first hypothesis is:
Hypothesis 1. Basic science is more likely to have patent citations than comparable clinical re-
search.
2.3. Combinational novelty and impact
We are interested in novel science because of its high-risk yet high-return particularity. Rev-
olutionary progresses in science and technology often need to break away from existing accepted
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paradigms (Kuhn, 1962) and tend to make novel combinations of previous components (Fleming,
2001). Yet, the lack of fit to prevailing paradigms makes their recognition difficult and delayed.
Indeed, novelty is an extensively studied mechanism of breakthrough recognition, and numerous
studies have suggested that there is bias against novelty (Boudreau et al., 2016; Chai and Menon,
2019; Wang et al., 2017).
The notion of novelty from a combinational perspective is prevalent in the innovation literature.
It has been studied for both scientific and technological innovations. Novel science has been opera-
tionalized as making combinations of existing knowledge components that have not been combined
before. Uzzi et al. (2013) viewed a scientific journal as one knowledge component and calculated a
z-score for each journal pair by comparing the observed frequency in the bibliographies of papers
published in a year with expected frequency by chance. A paper’s conventionality and novelty
are then defined as the median and 10th-percentile of the z-score distribution over its referenced
journal pairs. Using the two indicators, they found that papers with the highest scientific impact
are those that exhibit both high novelty and high conventionality. Foster et al. (2015) looked at
chemical-chemical combinations and found that papers examining new combinations of chemicals
are more likely to have high impact than papers studying conservative chemical pairs. Boudreau
et al. (2016) treated a Medical Subject Heading (MeSH) term as a knowledge component and mea-
sured the novelty of a research proposal as the fraction of MeSH pairs that have not been used in the
previous literature. They found that there is a systematic bias against novel proposals. Wang et al.
(2017) quantified novelty by looking at pairs of referenced journals, and their analysis reinforced
earlier findings about the bias against novel science.
Turning to the technology domain, Fleming (2001) found that patents that make new combi-
nations have more variability, which can give rise to both success and failure in terms of forward
patent citations. Sarah and Keyvan (2014) developed a novelty measure based on topic-modeling
of text and found that new topic originated patents are featured with local search and both broader
recombinations and novelty are linked to economic value of patents. Verhoeven et al. (2016) mea-
sured technological novelty of patents with respective to both recombination and knowledge origin,
as manifested by SNPRs, and found that technologically novel patents are more likely to receive
high forward patent citations and at the same time exhibit higher dispersion in such citations.
Based on these works, our second hypothesis is:
Hypothesis 2. Novel science is more likely to have patent citations than comparable non-novel
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research.
3. Data and Methods
3.1. Sample selection
To study the characteristics of scientific publications with technological impact, we link their
information in the scientific domain with information in the technology space. The unit of our
analysis is a scientific paper. The corpus of papers is those indexed in the MEDLINE database
and published between 1980 and 1999. MEDLINE is among the most comprehensive bibliography
datasets for the biomedical research literature. We obtain additional information, such as number
of references and author affiliations, from the Web of Science (WoS) database. We only consider
documents that are articles based on both the “Publication Type” tag in MEDLINE, as oper-
ationalized from https://icite.od.nih.gov/help, and document type specified in WoS. We further
limit our analysis to papers whose WoS Subject Category (SC) belongs to science and technology,
as social sciences and arts and humanity fields may be less likely to have technological impact.
These steps leave us with 3 737 751 unique papers. We assign research fields of papers based on
their SC. Papers with multiple SCs are counted multiple times as individual observations, and our
final dataset consists of 5 611 286 observations.
We measure technological impact of our cohort of papers using citations received from utility
patents granted at the USPTO between 1976 and 2012. We use a dataset that matched their
front-page non-patent references to MEDLINE, so that for each and every non-patent reference, we
know if and which MEDLINE paper it refers to (Ke, 2018). The matched results have an accuracy
of 97%.
3.2. Dependent variables
We introduce several dependent variables in our attempt to capture various dimensions of tech-
nological impact of scientific publications. The first one is whether the focal paper has achieved
technological impact, that is, whether it has been cited by patents granted up until 2012. For the
subset of papers with technological impact, we further consider the following variables that quantify
various elements of technological impact:
• Intensity of impact, as measured by the number of citing patents;
8
Table 1: Summary statistics of variables
Variable Mean Std. Dev. Min Max N
cited by patent 0.112 0.315 0 1 5 611 286
# patent citation 0.510 4.407 0 2 739 5 611 286
patent citation lag 9.550 5.457 0 32 628 168
# years to maximum patent citation 1.128 2.869 0 30 628 168
# citing IPC 2.784 2.144 0 76 628 168
year 1990.826 5.746 1980 1999 5 611 286
basicness 1.024 0.894 0 2 5 611 286
NoveltyCat 0.632 0.579 0 2 5 611 286
scientific citation 31.795 95.645 0 59 330 5 611 286
journal Impact Factor 2.098 2.52 0.001 39.104 5 473 178
international collaboration 0.1 0.3 0 1 4 358 488
# MeSH terms 12.212 4.139 2 57 5 611 286
# references 19.453 14.103 0 1 698 5 611 286
# authors 4.073 2.608 1 546 5 611 286
• Time lag of impact, as defined as the number of years passed from the publication year to the
year when first patent citation occurred;
• Longevity of impact, as quantified by the number of years from the year when the first citation
occurred to the year when the paper got the most citations;
• Scope of impact, as operationalized as the number of unique IPC (International Patent Clas-
sification) classes at the four-character level1.
Moreover, since patents at the USPTO are originated from many countries, although mainly the
US, and assigned to diverse types of organizations (e.g., universities and companies), for robustness
check, we restrict citing patents that are (1) from the US and (2) from US companies, and for both
cases, recalculate all the introduced dependent variables.
3.3. Independent variables
Two independent variables of interest are basicness and novelty. Both of them are measured
based on MeSH terms, which are controlled vocabularies used for indexing and retrieving MEDLINE
papers. The list of MeSH terms of a paper is assigned by trained librarians at the National Library
of Medicine (NLM) rather than authors, therefore is not subject to manipulation.
1E.g., “C07D” represents Heterocyclic Compounds.
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Table 2: Fraction of papers that are cited by patents at the USPTO.
Basicness NoveltyCat
Overall 0 1 2 0 1 2
# papers 5 611 286 2 177 939 1 121 093 2 312 254 2 352 488 2 969 692 289 106
% cited by patents 11.19 4.54 18.76 13.80 7.94 13.50 13.96
% cited by US patents 8.84 3.64 15.04 10.75 6.20 10.71 11.21
% cited by US company patents 5.66 2.38 9.52 6.87 3.94 6.85 7.44
Basic and clinical research are the two broad types of science conducted within biomedical re-
search. Clinical research is defined as “research with human subjects”2, whereas basic research
advances understanding of “living systems and life processes”3. As such, basic research is con-
ducted mostly at the level of cells and non-human animals, oftentimes using model organisms such
as Caenorhabditis elegans and Saccharomyces cerevisiae. Therefore, one widely used criteria to
distinguish whether a paper is basic science or clinical research is to check whether its associated
MeSH terms have cell-, animal-, and human-related terms (Ke, 2019b). Based on this, we introduce
a categorical variable to indicate three levels of basicness: (1) clinical research (basicness = 0), if the
MeSH terms of the focal paper contain only human-related terms; (2) moderately basic (basicness
= 1), if both human and cell/animal terms are present in the MeSH terms; and (3) highly basic
(basicness = 2), if there are only cell/animal terms.
In terms of novelty, we follow the literature that assesses novelty from the combinatorial per-
spective. In particular, similar to Boudreau et al. (2016), we compare pairwise combinations of
MeSH terms with the existing literature. We first calculate the novelty score of the focal paper
by looking at all the n(n − 1)/2 pairs of MeSH terms, with n denoting the number of terms, and
counting the fraction of MeSH pairs that have not been combined in the entire previous literature,
as captured by the MEDLINE database. We then construct our novelty measure as a categorical
variable, which has three levels: (1) non-novel (NoveltyCat = 0), if the focal paper makes no new
MeSH combination (novelty score 0); (2) moderately novel (NoveltyCat = 1), if the paper has at
least one new combination (novelty score > 0) but the novelty score is smaller than the top 5%
among papers clustered by subject category and year; and (3) highly novel (NoveltyCat = 2), if the
novelty score is among the top 5%.
2https://grants.nih.gov/grants/glossary.htm#ClinicalResearch
3https://www.nigms.nih.gov/Education/Pages/factsheet CuriosityCreatesCures.aspx
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3.4. Control variables
We use regression modeling techniques to understand how basicness and novelty are associated
with technological impact, while controlling for other potential confounding factors that may have
effects on patent citations as well as basicness and novelty. In light of previous studies, we take the
following control variables into consideration.
The first one is the number of scientific citations—the number of scientific papers that cite the
focal paper. Here we strict citing papers to those that were published up to 2012, since we count
patent citations until that year. We consider this variable because prior works have found that
scientific impact is positively associated with both technological impact (Ke, 2018; Popp, 2017) and
novelty (Uzzi et al., 2013).
We control for the venue of the focal paper using the journal Impact Factor (IF), as journals
with high IF have high prestige, which may increase the visibility and facilitate the diffusion of the
paper to the technology sphere.
We further include an indicator encoding whether a paper involves international collaboration,
as prior studies have established its linkage to novelty (Wagner et al., 2019).
Other control variables are the number of MeSH terms, number of references, and number of
authors. They are commonly considered confounders and shown to have relations to novelty (Chai
and Menon, 2019; Uzzi et al., 2013) and technological impact (Popp, 2017).
Finally, we create dummy variables for the WoS Subject Category and publication year. Our
estimations, therefore, capture within-field and within-year differences; that is, the effects of ba-
sicness and novelty on technological impact are compared within papers in the same research field
and published in the same year.
Table 1 reports the summary statistics of our variables.
4. Results
4.1. Direct technological impact
Table 2 shows that the characterization of papers as basic science links to higher probabilities
of achieving technological impact, relative to clinical research. Overall, 11.2% of papers are cited
by patents that are granted until 2012. While 4.5% of clinical research papers (basicness = 0) have
technological impact, 13.8% of highly basic papers—those with only cell/animal MeSH terms—do
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so. Interestingly, the group of moderately basic papers (basicness = 1) has the highest (18.8%)
fraction with technological impact. This means that papers that exhibit both the basic science
component and the clinical research component are most likely to be listed as prior art by patented
inventions. The same trend is observed if we limit citing patents to those from US organizations or
from US companies.
As for novelty, as indicated from Table 2, published biomedical literature displays low level of
novelty, with 41.9% of papers not introducing any new pairs of MeSH terms. This is consistent
with previous studies (Foster et al., 2015; Rzhetsky et al., 2015). Table 2 reports that 7.9% of these
non-novel papers are cited by patents, but the fraction is much higher for novel papers. For the
group of moderately novel papers (NoveltyCat = 1), a much higher fraction (13.5%) of papers get
cited by patents, and for the highly novel group, 14% of papers are cited by patents. Again, this
trend is robust if we consider only US patents or US company patents.
Next, we perform a series of logistic regressions to study the effects of basicness and novelty on
technological impact, while controlling for the research field and publication year effects and other
potential confounding factors as described before. In all models, the dependent variable is whether a
paper has been directly cited by patents granted up to 2012. Table 3 presents the modeling results,
confirming positive associations found from Table 2. While Model 1 in Table 3 is the baseline where
we included only control variables, Models 2–5 add independent variables. The reductions of BIC
from Model 1 provide very strong support for Models 2–5.
Let us elaborate the modeling results. Model 2 only examines the effect of basicness. We find
that basic science is more likely to have technological impact than clinical research, and the size of
such positive effect is large. As indicated from Model 2, after controlling for confounders, papers
with intermediate level of basicness (basicness = 1) have e0.904−1 = 147% higher odds of being cited
by patents than the odds for comparable clinical research papers in the same field and published
in the year. For highly basic papers, there is 104% increase in the odds of gaining technological
impact. That moderately basic papers have a more pronounced effect on technological impact than
highly basic papers indicates that papers that are most likely to get patent citations is those that
have both basic science and clinical medicine components and resonates with the argument made
by Gittelman (2016) that it is necessary for basic research to embed into clinical science to advance
the understanding of the biological basis of diseases.
Model 3, which focuses on the novelty aspect only, indicates a significant positive effect of novelty
12
Table 3: Logistic regression results of whether a paper has been directly cited by USPTO patents granted until 2012.
(1) (2) (3) (4) (5)
scientific citation (ln) 0.733∗∗∗ 0.751∗∗∗ 0.733∗∗∗ 0.750∗∗∗ 0.751∗∗∗
(0.00159) (0.00161) (0.00159) (0.00161) (0.00161)
Impact Factor 0.0416∗∗∗ 0.0350∗∗∗ 0.0412∗∗∗ 0.0350∗∗∗ 0.0349∗∗∗
(0.000596) (0.000592) (0.000597) (0.000593) (0.000593)
# MeSH 0.0130∗∗∗ 0.00731∗∗∗ 0.00407∗∗∗ 0.0000565 0.000257
(0.000378) (0.000383) (0.000401) (0.000406) (0.000406)
# ref (ln) 0.0407∗∗∗ -0.0310∗∗∗ 0.0449∗∗∗ -0.0241∗∗∗ -0.0240∗∗∗
(0.00239) (0.00242) (0.00240) (0.00243) (0.00243)
# author (ln) 0.236∗∗∗ 0.241∗∗∗ 0.235∗∗∗ 0.239∗∗∗ 0.239∗∗∗
(0.00295) (0.00300) (0.00295) (0.00300) (0.00300)
basicness=1 0.904∗∗∗ 0.873∗∗∗ 0.918∗∗∗
(0.00507) (0.00508) (0.00770)
basicness=2 0.714∗∗∗ 0.679∗∗∗ 0.676∗∗∗
(0.00502) (0.00504) (0.00705)
NoveltyCat=1 0.249∗∗∗ 0.204∗∗∗ 0.196∗∗∗
(0.00346) (0.00349) (0.00715)
NoveltyCat=2 0.499∗∗∗ 0.423∗∗∗ 0.663∗∗∗
(0.00666) (0.00670) (0.0153)
basicness=1 × NoveltyCat=1 -0.0328∗∗∗
(0.00938)
basicness=1 × NoveltyCat=2 -0.396∗∗∗
(0.0199)
basicness=2 × NoveltyCat=1 0.0271∗∗
(0.00846)
basicness=2 × NoveltyCat=2 -0.234∗∗∗
(0.0178)
Constant -6.434∗∗∗ -6.512∗∗∗ -6.501∗∗∗ -6.562∗∗∗ -6.575∗∗∗
(0.0180) (0.0181) (0.0180) (0.0181) (0.0185)
Field fe X X X X X
Year fe X X X X X
Observations 5473178 5473178 5473178 5473178 5473178
Pseudo R2 0.198 0.207 0.200 0.208 0.209
BIC 3089148 3055890 3081097 3050394 3050022
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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on technological impact. After controlling for confounders, we expect 28.3% and 64.7% increase in
the odds of receiving patent citations respectively for moderately and highly novel papers, compared
to non-novel papers in the same field and published in the same year.
Models 4 considers both basicness and novelty, reassuring their positive influence on technolog-
ical impact, regardless of whether or not controlling for each other. The comparison of Model 4
to Model 2 indicates that the coefficients of basicness do not decrease much after additionally con-
trolling for novelty. On the other hand, comparing Model 4 to Model 3 indicates that additionally
controlling for basicness decrease the positive coefficient of novelty.
To further understand the effects of basicness and novelty, in the left panel in Fig. 1, we show the
predictive margins of the 9 combinations of different values of basicness and novelty. The predictive
margin of a particular combination, for example moderately basic and moderately novel (basicness
= 1, NoveltyCat = 1), is the average probability over all observations, where the probability of each
observation is computed by setting its basicness and NoveltyCat values to 1 and fixing all other
independent variable values as observed, i.e., treating it as though it were moderately basic and
moderately novel, regardless of what its actual basicness and novelty are. We can see that papers
that are simultaneously moderately basic and highly novel are most likely to obtain patent citations.
We also observe that at each level of basicness, highly novel papers have larger probabilities to get
patent citations than moderately novel papers, which are more likely to get cited than non-novel
papers. The extent of differences between these margins is not equal, suggesting that the margin
effect of novelty is dependent on basicness. This can be readily seen from Table 4 (the third and
fourth columns), where we present the average marginal effects (AME) of novelty. AME for being
moderately novel is 1.6%; that is, on average a moderately novel paper’s probability of being cited
by patents is 1.6 percentage points higher than it is for non-novel novel. The effect differs greatly at
varying levels of basicness; less than 1.2 percentage point for clinical papers and 1.8 percentage point
for highly basic papers. A similar conclusion can be drawn for highly novel papers. On average,
they have a 3.6 percentage point higher probability than non-novel papers, which decreases to 2.6
for clinical papers and increases to 4.4 for moderately basic papers.
Model 5 adds the basicness-novelty interaction term to Model 4. Again, for ease of interpretation,
we plot the predictive margins in the right panel in Fig. 1. The results in general agree with the
model without the interaction term; that is, the combination of moderately basic and highly novel
has the most pronounced effect on getting patent citations, novel papers have largest probabilities
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Figure 1: Predictive margins of combinations of basicness and novelty (left) without and (right) with the interaction
term.
Table 4: Average marginal effects (AME) of novelty, varied by basicness and whether including the interaction term.
All AMEs are statistically significant, with z greater than 50 for the model without interaction and greater than 20
for the model with interaction.
NoveltyCat Basicness AME 95% CI AME 95% CI
1 – 0.0164 0.0158 0.0169 0.0161 0.0155 0.0166
1 0 0.0116 0.0112 0.0120 0.0111 0.0103 0.0119
1 1 0.0201 0.0194 0.0208 0.0163 0.0151 0.0175
1 2 0.0180 0.0174 0.0186 0.0197 0.0189 0.0205
2 – 0.0362 0.0350 0.0375 0.0374 0.0362 0.0387
2 0 0.0261 0.0251 0.0270 0.0442 0.0418 0.0466
2 1 0.0443 0.0428 0.0458 0.0274 0.0247 0.0301
2 2 0.0398 0.0385 0.0412 0.0403 0.0385 0.0421
to get cited by patents at each level of basicness, and the differences of probabilities among different
categories of novelty depend on levels of basicness (the last two columns in Table 4).
Table 3 also reveals a positive association between scientific impact and technological impact,
in consistence with previous literature (Ke, 2018; Popp, 2017). The positive linkage also holds for
journal Impact Factor, indicating that papers published in more prestigious journals are more likely
to be cited by patents than comparable papers.
4.2. Features of technological impact
In the previous section, we have established that both basicness and novelty are positively
associated with the likelihood to attain technological impact. We now restrict our analysis to
the subsample of the 628 168 papers that are directly cited by patents and ask: Within this set
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Table 5: Characteristics of technological impact of papers that are cited by USPTO patents.
Basicness NoveltyCat
Overall 0 1 2 0 1 2
# papers cited by patents 628 168 98 803 210 298 319 067 186 775 401 025 40 368
Average patent citations 4.55 3.60 4.97 4.57 4.12 4.68 5.33
Average time lag 9.55 10.54 8.90 9.67 10.06 9.32 9.42
Average duration 1.13 0.84 1.24 1.14 1.02 1.16 1.31
Average # of citing IPC 2.78 2.00 3.07 2.84 2.55 2.87 2.97
of publications with technological impact, do the two characteristics still associate with various
dimensions of technological impact? Here we examine four aspects, namely the intensity, time lag,
longevity, and scope of the impact.
4.2.1. Patent citation intensity
Let us first focus on the intensity of technological impact, as measured by the number of patent
citations. Similar to citations received from scientific papers, citation count from patents is also
heavily distributed, as observed in Ke (2018). Within the studied sample, 254 905 (40.6%) papers
are cited by only one patent, but there is one paper that has attracted 2 739 patent citations.
Table 5 reports that on average clinical research papers have 3.6 patent citations, which is lower
than citations of either moderately basic papers or highly basic papers. Novel science also possesses
this superiority in achieving intense technological impact. While non-novel papers are cited by 4.1
patents, highly novel papers have 5.3 patent citations. We run negative binomial (NB) regression
to examine whether the positive association persists after controlling for potential confounders. NB
model is employed because patent citation is an over-dispersed variable. Model 2 in Table 6 presents
the modeling results in the full model where all control variables are included, while Model 1 is the
baseline model. We can confirm that both basic science and novel science are positively linked to
the intensity of technological impact. Moderately and highly basic papers have respectively 14.9%
and 11.8% more patent citations than comparable clinical papers. Moderately novel papers have
3.4% more patent citations than non-novel papers, and the effect size is more pronounced for highly
novel papers, reaching to 13.5%.
4.2.2. Patent citation time lag
Next, we assess the time lag of technological impact, as defined as the number of years taken
to get the first patent citation after the publication of the focal paper. Existing theories suggest
16
that novel science faces resistance of acceptance from existing paradigms, and previous studies
have empirically documented that novel science experiences delayed recognition in the scientific
community. Given these works, it is important to ask whether delayed recognition for novel science
also occurs in the technology community.
Table 5 indicates that this is not the case. Compared to clinical research papers that have
10.5 years of lag, it takes a smaller number of years for basic science papers to get the first patent
citation. Similarly, novel science has a shorter lag than that of non-novel papers. We further use
OLS to model the effects of basicness and novelty on time lag. Model 4 in Table 6 show negative
associations, indicating that it requires less time for basic science papers and novel papers to get
cited by patents than their respective counterparts. These results suggest that, on the contrary to
what happens in the scientific domain, novel science appears not to display the delayed recognition
phenomenon.
Why do novel science papers have a shorter time lag in getting the first patent citation than
non-novel papers? Here we provide one explanation based on a recent work by Chai and Menon
(2019)4. That is, novel papers cover less popular topics, in contrast to non-novel papers covering
more popular topics, and this makes novel science face a less fierce competition for limited attention
than non-novel papers, which facilitates the diffusion of novel science to the technology community.
To provide evidence for this hypothesis, we first calculate the relative popularity of a MeSH term
in a year, defined as the fraction of papers with that term among all papers published in that year.
For each paper, we then take the average of the popularities of its MeSH terms as the indicator to
measure to what extent it covers popular topics. Fig. 2 shows that for papers with technological
impact, novel science covers less popular topics than non-novel science and this is consistent across
years, supporting our hypothesis that the popularity of studied topics in a paper may have an effect
on the time lag of technological impact.
4.2.3. Patent citation longevity
We also look at the other feature regarding the timing of technological impact, namely the
longevity of impact, as quantified by the number of years taken to reach the maximum yearly
patent citations from the year when the first citation occurred. Table 5 suggests that basic science
4We thank the reviewer for suggesting this.
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Figure 2: MeSH term popularities of papers grouped by their novelty.
papers have greater longevity than clinical research papers, so have novel papers than non-novel
ones. OLS regression modeling assures that this positive influence of basicness and novelty on
longevity holds after controlling for confounders, as demonstrated in Model 6 in Table 6.
4.2.4. Patent citation scope
Finally, we examine if basic science and novel science’s technological impact spans broader
technological domains, as operationalized by the number of 4-character IPC classes of their citing
patents. Table 5 shows that this is indeed the case. While a clinical paper’s citing patents on average
belong to 2 classes, moderately basic and highly basic papers’ citing patents respectively come from
3.1 and 2.8 classes. As for novelty, non-novel papers are cited by 2.5 IPC classes, in contrast to 3
classes for the highly novel papers. Further OLS modeling confirms positive associations between
the scope of technological impact and basicness as well as novelty (Model 8 in Table 6). Note
that here we consider not only the complete set of control variables as before but also the number
of patent citations as another confounder, because papers with a larger number of citing patents
would by chance have more citing technological classes. Moderately basic papers have 0.33 more
citing class than clinical papers, and 0.24 more for highly basic papers. Moderately and highly
novel papers have respectively 0.03 and 0.1 more citing class than comparable non-novel papers.
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Table 6: Results of regression modeling of technological impact.
Intensity (NB) Time lag (OLS) Longevity (OLS) Scope (OLS)
(1) (2) (3) (4) (5) (6) (7) (8)
scientific citation (ln) 0.281∗∗∗ 0.281∗∗∗ -0.362∗∗∗ -0.369∗∗∗ 0.446∗∗∗ 0.449∗∗∗ 0.109∗∗∗ 0.113∗∗∗
(0.00122) (0.00123) (0.00622) (0.00623) (0.00352) (0.00353) (0.00177) (0.00177)
Impact Factor 0.0109∗∗∗ 0.0105∗∗∗ -0.0531∗∗∗ -0.0516∗∗∗ 0.0133∗∗∗ 0.0127∗∗∗ 0.0194∗∗∗ 0.0189∗∗∗
(0.000385) (0.000384) (0.00191) (0.00191) (0.00108) (0.00108) (0.000532) (0.000532)
# MeSH -0.00380∗∗∗ -0.00600∗∗∗ -0.00751∗∗∗ 0.00648∗∗∗ -0.00354∗∗∗ -0.00727∗∗∗ 0.00467∗∗∗ 0.000954∗
(0.000326) (0.000349) (0.00156) (0.00167) (0.000885) (0.000945) (0.000435) (0.000464)
# ref (ln) -0.122∗∗∗ -0.129∗∗∗ 0.120∗∗∗ 0.162∗∗∗ -0.145∗∗∗ -0.159∗∗∗ 0.0263∗∗∗ 0.00667∗
(0.00229) (0.00232) (0.0107) (0.0109) (0.00607) (0.00615) (0.00299) (0.00302)
# author (ln) 0.0730∗∗∗ 0.0707∗∗∗ -0.394∗∗∗ -0.381∗∗∗ 0.143∗∗∗ 0.139∗∗∗ 0.0326∗∗∗ 0.0274∗∗∗
(0.00254) (0.00255) (0.0124) (0.0124) (0.00700) (0.00703) (0.00344) (0.00346)
basicness=1 0.139∗∗∗ -0.754∗∗∗ 0.246∗∗∗ 0.326∗∗∗
(0.00490) (0.0227) (0.0128) (0.00630)
basicness=2 0.112∗∗∗ -0.554∗∗∗ 0.187∗∗∗ 0.237∗∗∗
(0.00471) (0.0219) (0.0124) (0.00610)
NoveltyCat=1 0.0331∗∗∗ -0.218∗∗∗ 0.0513∗∗∗ 0.0285∗∗∗
(0.00320) (0.0151) (0.00855) (0.00420)
NoveltyCat=2 0.127∗∗∗ -0.494∗∗∗ 0.200∗∗∗ 0.0997∗∗∗
(0.00578) (0.0278) (0.0157) (0.00771)
patent citation (ln) 1.579∗∗∗ 1.574∗∗∗
(0.00193) (0.00193)
Constant 0.268∗∗∗ 0.235∗∗∗ 18.08∗∗∗ 18.25∗∗∗ -0.496∗∗∗ -0.555∗∗∗ 0.353∗∗∗ 0.302∗∗∗
(0.0172) (0.0172) (0.0811) (0.0812) (0.0458) (0.0460) (0.0226) (0.0226)
lnalpha -0.204∗∗∗ -0.207∗∗∗
(0.00210) (0.00210)
Field fe X X X X X X X X
Year fe X X X X X X X X
Observations 615981 615981 615981 615981 615981 615981 615981 615981
(Pseudo) R2 0.0384 0.0389 0.179 0.181 0.0526 0.0535 0.588 0.590
BIC 3104621 3103322 3719125 3717606 3016986 3016484 2142837 2139976
Standard errors in parentheses. NB: negative binomial.
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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4.3. Robustness tests
We perform several additional regressions to test the robustness of our findings. First, in all
the analyses presented as far, we have not taken into account the variable whether a paper involves
international collaboration, because there is a large fraction (22%) of papers without enough af-
filiation data that allows us to infer the variable (Table 1). This is especially the case for papers
in earlier years. Our results, nevertheless, remain robust if we restrict our sample to those papers
with known value for this variable and included it as another control variable (Tables A.1 and A.2).
Interestingly, international collaboration has a negative effect on achieving technological impact,
in contrast to its positive effect in the scientific community where papers involving international
collaboration have more scientific citations.
Patents may originate from varying types of organizations. Although the vast majority of
patents are assigned to companies, public research organizations still own patents, especially in our
focused sector of life and biomedical science. As the contribution to private sector innovations is of
particular interest to many policymakers, when measuring technological impact, we only considered
citing patents (1) from US organizations and from (2) US companies. We then repeat all analyses
and find that all the findings hold (Tables A.3 and A.4; Tables A.5 and A.6).
We have used negative binomial regression to model the intensity of patent citations for papers
with technological impact. To further examine the robustness of our results, we have performed
two checks: (1) OLS with log10-transformed number of patent citations as the dependent variable,
and (2) logit models where the dependent variables are whether the number of patent citations is
ranked into the top 5% (or top 10%) for papers in the same field and the same year. Both checks
consolidate our findings that basic science and novel science have positive effects on number of
patent citations (Table A.7).
Finally, we have duplicated papers with multiple SCs as individual observations. We adopted
an alternative way, whereby we chose from a paper’s associated SCs the one that is most presented
in its reference list. This practice has also been used in previous literature (e.g., Verhoeven et al.
(2016)). Our findings still stand (Tables A.8 and A.9).
5. Concluding discussion
In this work, we have studied science-technology interaction from the science perspective by
identifying which characteristics of scientific publications are more likely to garner technological
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impact. We have paid attention to two important features, namely basicness and novelty. Drawing
on a large-scale corpus consisting of 3.8 million MEDLINE research articles published between 1980
and 1999 and all the USPTO utility patents granted from 1976 to 2012, we have systematically
investigated the relationships between technological impact and basicness and novelty. We found
that both features have positive associations with technological impact and the effect sizes are large.
In particular, our estimations indicate that, after controlling for confounders, the odds of being cited
by patents is 139% higher for moderately basic science papers than comparable clinical research
papers, and 97% higher for highly basic papers. Moderately and highly novel papers’ odds of being
cited by patents increase 23% and 53%, compared to non-novel papers. Such superiority in obtaining
technological impact for basic science and novel publications is robust even after controlling for their
scientific impact and the prestige of the journal where they were published, suggesting potential
factors beyond scientific quality and venue visibility arising for the technological impact. Moreover,
the positive effects are persistent across the study period.
We have further confined the sample to papers that are cited by patents and explored techno-
logical impact profiles of those papers. We found that both basic science papers and novel papers
consistently have more patent citations and a broader scope of technological impact. Moreover, it
takes less time for both of them to reach to the technology space. This relative absence of time
delay of novel science is in contrast to what happens in the scientific community, where novel science
has displayed a delayed recognition in gaining scientific impact.
Our work contributes to the ongoing understanding of the interaction between science and
technology and contrasts to many earlier studies that examined the linkage from the technology
perspective. First, we find that in biomedicine, basic research papers are more likely to get patent
citations. Although the role of basic science in technology development has been discussed previ-
ously (Lim, 2004; McMillan et al., 2000; Narin et al., 1997), our systematic study differs from them
in several ways. Specifically, analyses presented in both Narin et al. (1997) and McMillan et al.
(2000) were retrospective; they started from patents and traced back to examine which types of
papers get cited by patents. Ours, by contrast, is prospective; our starting point is all published
papers and we examine if basic science papers are more likely to get patent citations than clinical
papers. Such a distinction is important, because patent-centered, retrospective studies fail to take
population papers into account, and the observation made in Narin et al. (1997) and McMillan et al.
(2000) that cited science is basic could simply due to the fact that there are more basic papers, as
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we have found previously (Ke, 2019b), rather than their advantage in gaining technological impact.
Our work is a direct demonstration of the advantage of basic science. Moreover, we quantified
through regression techniques the effect of basicness on the likelihood of receiving patent citations
and further explored different characteristics of technological impact. Both features were absent
in Narin et al. (1997) and McMillan et al. (2000). Our work asks a different research question
from the one asked in Lim (2004), which focused on firms and studied the relationship between
their innovation output, as measured by number of patents, and within-firm basic/applied research
activities, as measured by number of publications.
Second, we studied the combination of basicness and novelty and potential interactions between
them. We found that papers featuring moderately basic and highly novel have largest probabilities
of getting cited by patents and at each level of basicness, highly novel papers are most likely to accrue
patent citations. Moreover, we presented a large-scale and systematic study of the role of novelty
in technological impact; we looked at every research article indexed in the most comprehensive
database for biomedical research literature in a 20-year period, as opposed to papers published
in a single year. The scale of a corpus matters, because conclusions drawn from a large-scale
corpus may point to general and robust features of the system rather than properties that are
potentially constrained by peculiarities of a small-scale corpus. This aligns with recent interests in
computational social science (Lazer et al., 2009) and science of science (Fortunato et al., 2018; Zeng
et al., 2017).
Our findings speak to the ongoing discussions in the science policy literature on the role of basic
science and novel science. Recently, there is an increasing pressure to demonstrate the societal
impact of science. In biomedicine, basic biomedical research has received comments about its
relevance in improving societal health, based on the superficial view that basic science oftentimes
uses model organisms as study subjects. However, by using model organisms, basic science sheds
light on life processes and disease mechanisms, and knowledge produced from basic science “leads
to better ways to predict, prevent, diagnose, and treat disease,” therefore improving patient health.
Moreover, in drug development, there is a linear pipeline where basic science must precede clinical
research. Only after basic science with certain goals such as target and drug identification and
preclinical validation has been fulfilled can the development enter the clinical trial and registration
stage. Our work adds another dimension of the impact of basic science, that is, it contributes to
technology development.
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As for novelty, there have been increasing concerns that funding agencies are conservative in
choosing projects, favoring safe ones and biasing against novel proposals that plan to chart less
explored research topics (Boudreau et al., 2016). Yet, prior studies suggested that funding policies
are among the key drivers of scientific creativity (Azoulay et al., 2011), and novel science is an
important source of scientific breakthrough (Uzzi et al., 2013). Our work aligns with these lines of
inquiry and provides empirical, supporting evidence for alleviating the bias against novelty, or even
encouraging the pursuit of novel science, because it contributes to the development of technological
innovations.
We have looked at whether and when a scientific paper has technological impact as well as the
intensity and scope of the impact, without assessing the characteristics of citing patents. Future
work can explore whether basic and novel science are more likely to have technological impact
from high quality, novel, or disruptive patents. Moreover, we have only considered the biomedical
research area and patents at the USPTO, it remains to be seen if the advantage of achieving
technological impact still holds for other scientific disciplines like physical sciences and engineering
and for patents from other patent offices. In addition, uncovering more ex ante characteristics
of scientific publications, such as interdisciplinarity, may also serve as another topic for future
investigations. Finally, our work raises several questions related to the context and pathway from
basic and novel science to technological innovations. For example, do author-inventor play a role in
forming the linkage? Does geographic distance or science-technology knowledge relatedness matter
more? Answers to these questions would further advance the understanding of science-technology
linkage.
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Table A.1: Logit regression of direct patent citation. All models include whether a focal paper involves international
collaboration as another control variable. The reductions of BIC provide very strong support for Models 2–5.
(1) (2) (3) (4) (5)
scientific citation (ln) 0.730∗∗∗ 0.750∗∗∗ 0.730∗∗∗ 0.749∗∗∗ 0.750∗∗∗
(0.00178) (0.00180) (0.00178) (0.00180) (0.00181)
Impact Factor 0.0432∗∗∗ 0.0359∗∗∗ 0.0429∗∗∗ 0.0360∗∗∗ 0.0359∗∗∗
(0.000671) (0.000665) (0.000672) (0.000666) (0.000666)
# MeSH 0.0142∗∗∗ 0.00874∗∗∗ 0.00560∗∗∗ 0.00191∗∗∗ 0.00212∗∗∗
(0.000412) (0.000417) (0.000437) (0.000442) (0.000442)
# ref (ln) 0.0374∗∗∗ -0.0446∗∗∗ 0.0418∗∗∗ -0.0374∗∗∗ -0.0373∗∗∗
(0.00290) (0.00295) (0.00291) (0.00295) (0.00295)
# author (ln) 0.233∗∗∗ 0.242∗∗∗ 0.233∗∗∗ 0.239∗∗∗ 0.240∗∗∗
(0.00325) (0.00330) (0.00325) (0.00331) (0.00331)
international=1 -0.0555∗∗∗ -0.0770∗∗∗ -0.0596∗∗∗ -0.0794∗∗∗ -0.0794∗∗∗
(0.00500) (0.00502) (0.00501) (0.00503) (0.00503)
basicness=1 0.911∗∗∗ 0.881∗∗∗ 0.939∗∗∗
(0.00554) (0.00556) (0.00846)
basicness=2 0.733∗∗∗ 0.700∗∗∗ 0.702∗∗∗
(0.00553) (0.00555) (0.00785)
novelty=1 0.243∗∗∗ 0.195∗∗∗ 0.199∗∗∗
(0.00383) (0.00386) (0.00790)
novelty=2 0.483∗∗∗ 0.402∗∗∗ 0.659∗∗∗
(0.00739) (0.00743) (0.0171)
basicness=1 × novelty=1 -0.0534∗∗∗
(0.0103)
basicness=1 × novelty=2 -0.411∗∗∗
(0.0219)
basicness=2 × novelty=1 0.0172
(0.00940)
basicness=2 × novelty=2 -0.253∗∗∗
(0.0199)
Constant -6.408∗∗∗ -6.473∗∗∗ -6.476∗∗∗ -6.524∗∗∗ -6.545∗∗∗
(0.0207) (0.0209) (0.0208) (0.0209) (0.0213)
Field fe X X X X X
Year fe X X X X X
Observations 4256126 4256126 4256126 4256126 4256126
Pseudo R2 0.195 0.204 0.197 0.206 0.206
BIC 2518857 2490432 2512673 2486381 2486058
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 29
Table A.2: Results of regression modeling of technological impact. All models include whether a focal paper involves international collaboration as another control variable.
Intensity (NB) Time lag (OLS) Longevity (OLS) Scope (OLS)
(1) (2) (3) (4) (5) (6) (7) (8)
scientific citation (ln) 0.280∗∗∗ 0.281∗∗∗ -0.361∗∗∗ -0.370∗∗∗ 0.444∗∗∗ 0.447∗∗∗ 0.109∗∗∗ 0.114∗∗∗
(0.00136) (0.00136) (0.00672) (0.00673) (0.00385) (0.00386) (0.00197) (0.00197)
Impact Factor 0.0106∗∗∗ 0.0103∗∗∗ -0.0520∗∗∗ -0.0501∗∗∗ 0.0130∗∗∗ 0.0123∗∗∗ 0.0190∗∗∗ 0.0183∗∗∗
(0.000426) (0.000425) (0.00206) (0.00206) (0.00118) (0.00118) (0.000591) (0.000591)
# MeSH -0.00296∗∗∗ -0.00500∗∗∗ -0.00900∗∗∗ 0.00349∗ -0.00190∗ -0.00538∗∗∗ 0.00480∗∗∗ 0.00130∗∗
(0.000351) (0.000376) (0.00164) (0.00175) (0.000942) (0.00101) (0.000471) (0.000502)
# ref (ln) -0.127∗∗∗ -0.136∗∗∗ 0.156∗∗∗ 0.206∗∗∗ -0.153∗∗∗ -0.169∗∗∗ 0.0301∗∗∗ 0.00844∗
(0.00270) (0.00273) (0.0124) (0.0126) (0.00711) (0.00720) (0.00356) (0.00360)
# author (ln) 0.0777∗∗∗ 0.0755∗∗∗ -0.396∗∗∗ -0.386∗∗∗ 0.149∗∗∗ 0.146∗∗∗ 0.0349∗∗∗ 0.0302∗∗∗
(0.00279) (0.00280) (0.0133) (0.0133) (0.00759) (0.00763) (0.00380) (0.00381)
international=1 -0.0909∗∗∗ -0.0912∗∗∗ 0.242∗∗∗ 0.249∗∗∗ -0.132∗∗∗ -0.134∗∗∗ -0.0126∗ -0.0162∗∗
(0.00427) (0.00427) (0.0199) (0.0198) (0.0114) (0.0114) (0.00569) (0.00568)
basicness=1 0.142∗∗∗ -0.770∗∗∗ 0.251∗∗∗ 0.326∗∗∗
(0.00532) (0.0240) (0.0138) (0.00687)
basicness=2 0.117∗∗∗ -0.599∗∗∗ 0.192∗∗∗ 0.238∗∗∗
(0.00514) (0.0234) (0.0134) (0.00670)
NoveltyCat=1 0.0310∗∗∗ -0.194∗∗∗ 0.0464∗∗∗ 0.0268∗∗∗
(0.00351) (0.0161) (0.00926) (0.00462)
NoveltyCat=2 0.117∗∗∗ -0.462∗∗∗ 0.171∗∗∗ 0.0942∗∗∗
(0.00635) (0.0297) (0.0170) (0.00850)
patent citation (ln) 1.586∗∗∗ 1.581∗∗∗
(0.00213) (0.00212)
Constant 0.266∗∗∗ 0.235∗∗∗ 17.90∗∗∗ 18.06∗∗∗ -0.514∗∗∗ -0.566∗∗∗ 0.371∗∗∗ 0.325∗∗∗
(0.0196) (0.0196) (0.0902) (0.0903) (0.0517) (0.0518) (0.0259) (0.0259)
lnalpha -0.218∗∗∗ -0.220∗∗∗
(0.00231) (0.00232)
Field fe X X X X X X X X
Year fe X X X X X X X X
Observations 511881 511881 511881 511881 511881 511881 511881 511881
(Pseudo) R2 0.0383 0.0387 0.174 0.177 0.0534 0.0543 0.588 0.590
BIC 2576365 2575315 3059500 3058168 2489328 2488926 1779725 1777346
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.3: Logit regression of direct patent citation. The dependent variables are based on patents assigned to US
organizations.
(1) (2) (3) (4) (5)
scientific citation (ln) 0.753∗∗∗ 0.769∗∗∗ 0.753∗∗∗ 0.768∗∗∗ 0.768∗∗∗
(0.00174) (0.00176) (0.00174) (0.00176) (0.00176)
Impact Factor 0.0421∗∗∗ 0.0368∗∗∗ 0.0418∗∗∗ 0.0369∗∗∗ 0.0368∗∗∗
(0.000608) (0.000605) (0.000609) (0.000606) (0.000606)
# MeSH 0.0128∗∗∗ 0.00702∗∗∗ 0.00385∗∗∗ -0.000266 -0.0000519
(0.000413) (0.000418) (0.000438) (0.000443) (0.000443)
# ref (ln) 0.0344∗∗∗ -0.0340∗∗∗ 0.0385∗∗∗ -0.0271∗∗∗ -0.0270∗∗∗
(0.00264) (0.00267) (0.00265) (0.00268) (0.00268)
# author (ln) 0.207∗∗∗ 0.208∗∗∗ 0.207∗∗∗ 0.206∗∗∗ 0.206∗∗∗
(0.00323) (0.00328) (0.00323) (0.00329) (0.00329)
basicness=1 0.886∗∗∗ 0.855∗∗∗ 0.894∗∗∗
(0.00560) (0.00561) (0.00851)
basicness=2 0.679∗∗∗ 0.644∗∗∗ 0.646∗∗∗
(0.00556) (0.00558) (0.00782)
NoveltyCat=1 0.250∗∗∗ 0.206∗∗∗ 0.199∗∗∗
(0.00383) (0.00385) (0.00791)
NoveltyCat=2 0.498∗∗∗ 0.424∗∗∗ 0.685∗∗∗
(0.00727) (0.00731) (0.0167)
basicness=1 × NoveltyCat=1 -0.0235∗
(0.0103)
basicness=1 × NoveltyCat=2 -0.406∗∗∗
(0.0216)
basicness=2 × NoveltyCat=1 0.0213∗
(0.00937)
basicness=2 × NoveltyCat=2 -0.261∗∗∗
(0.0195)
Constant -6.687∗∗∗ -6.754∗∗∗ -6.753∗∗∗ -6.804∗∗∗ -6.819∗∗∗
(0.0199) (0.0200) (0.0199) (0.0200) (0.0205)
Field fe X X X X X
Year fe X X X X X
Observations 5473178 5473178 5473178 5473178 5473178
Pseudo R2 0.193 0.201 0.195 0.202 0.202
BIC 2653494 2627529 2646846 2622929 2622616
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.4: Results of regression modeling of technological impact. The dependent variables are based on patents assigned to US organizations.
Intensity (NB) Time lag (OLS) Longevity (OLS) Scope (OLS)
(1) (2) (3) (4) (5) (6) (7) (8)
scientific citation (ln) 0.282∗∗∗ 0.282∗∗∗ -0.308∗∗∗ -0.314∗∗∗ 0.387∗∗∗ 0.389∗∗∗ 0.107∗∗∗ 0.111∗∗∗
(0.00151) (0.00151) (0.00693) (0.00694) (0.00377) (0.00377) (0.00196) (0.00196)
Impact Factor 0.0148∗∗∗ 0.0145∗∗∗ -0.0520∗∗∗ -0.0509∗∗∗ 0.0112∗∗∗ 0.0106∗∗∗ 0.0181∗∗∗ 0.0176∗∗∗
(0.000481) (0.000481) (0.00205) (0.00205) (0.00111) (0.00111) (0.000570) (0.000569)
# MeSH -0.00461∗∗∗ -0.00693∗∗∗ -0.00813∗∗∗ 0.00517∗∗ -0.00565∗∗∗ -0.00879∗∗∗ 0.00488∗∗∗ 0.00101
(0.000402) (0.000431) (0.00175) (0.00186) (0.000949) (0.00101) (0.000486) (0.000518)
# ref (ln) -0.128∗∗∗ -0.132∗∗∗ 0.0806∗∗∗ 0.122∗∗∗ -0.146∗∗∗ -0.157∗∗∗ 0.0295∗∗∗ 0.00865∗
(0.00281) (0.00285) (0.0120) (0.0121) (0.00651) (0.00660) (0.00334) (0.00338)
# author (ln) 0.0569∗∗∗ 0.0534∗∗∗ -0.339∗∗∗ -0.320∗∗∗ 0.130∗∗∗ 0.128∗∗∗ 0.0259∗∗∗ 0.0211∗∗∗
(0.00313) (0.00315) (0.0138) (0.0139) (0.00750) (0.00754) (0.00384) (0.00385)
basicness=1 0.114∗∗∗ -0.767∗∗∗ 0.193∗∗∗ 0.329∗∗∗
(0.00604) (0.0254) (0.0138) (0.00706)
basicness=2 0.0766∗∗∗ -0.510∗∗∗ 0.156∗∗∗ 0.250∗∗∗
(0.00578) (0.0246) (0.0134) (0.00683)
NoveltyCat=1 0.0368∗∗∗ -0.183∗∗∗ 0.0494∗∗∗ 0.0352∗∗∗
(0.00395) (0.0170) (0.00924) (0.00472)
NoveltyCat=2 0.140∗∗∗ -0.429∗∗∗ 0.204∗∗∗ 0.110∗∗∗
(0.00713) (0.0309) (0.0168) (0.00859)
patent citation (ln) 1.543∗∗∗ 1.539∗∗∗
(0.00217) (0.00217)
Constant 0.0668∗∗ 0.0408 17.88∗∗∗ 18.02∗∗∗ -0.272∗∗∗ -0.325∗∗∗ 0.350∗∗∗ 0.297∗∗∗
(0.0211) (0.0211) (0.0905) (0.0906) (0.0492) (0.0493) (0.0252) (0.0252)
lnalpha 0.256∗∗∗ 0.254∗∗∗
(0.00227) (0.00227)
Field fe X X X X X X X X
Year fe X X X X X X X X
Observations 615981 615981 486704 486704 486704 486704 486704 486704
(Pseudo) R2 0.0305 0.0308 0.183 0.185 0.0459 0.0466 0.573 0.575
BIC 2806520 2805789 2934397 2933240 2340726 2340415 1688376 1686016
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.5: Logit regression of direct patent citation. The dependent variables are based on patents assigned to US
companies.
(1) (2) (3) (4) (5)
scientific citation (ln) 0.734∗∗∗ 0.746∗∗∗ 0.734∗∗∗ 0.744∗∗∗ 0.745∗∗∗
(0.00204) (0.00205) (0.00204) (0.00205) (0.00205)
Impact Factor 0.0210∗∗∗ 0.0174∗∗∗ 0.0206∗∗∗ 0.0173∗∗∗ 0.0172∗∗∗
(0.000632) (0.000635) (0.000633) (0.000636) (0.000636)
# MeSH 0.0113∗∗∗ 0.00622∗∗∗ 0.00292∗∗∗ -0.000680 -0.000432
(0.000490) (0.000496) (0.000520) (0.000525) (0.000525)
# ref (ln) -0.0133∗∗∗ -0.0764∗∗∗ -0.00900∗∗ -0.0693∗∗∗ -0.0693∗∗∗
(0.00313) (0.00317) (0.00314) (0.00317) (0.00318)
# author (ln) 0.236∗∗∗ 0.239∗∗∗ 0.235∗∗∗ 0.236∗∗∗ 0.237∗∗∗
(0.00386) (0.00392) (0.00387) (0.00393) (0.00393)
basicness=1 0.812∗∗∗ 0.780∗∗∗ 0.828∗∗∗
(0.00678) (0.00679) (0.0103)
basicness=2 0.644∗∗∗ 0.609∗∗∗ 0.622∗∗∗
(0.00672) (0.00674) (0.00950)
NoveltyCat=1 0.241∗∗∗ 0.200∗∗∗ 0.206∗∗∗
(0.00462) (0.00464) (0.00962)
NoveltyCat=2 0.497∗∗∗ 0.430∗∗∗ 0.697∗∗∗
(0.00856) (0.00859) (0.0199)
basicness=1 × NoveltyCat=1 -0.0363∗∗
(0.0125)
basicness=1 × NoveltyCat=2 -0.413∗∗∗
(0.0256)
basicness=2 × NoveltyCat=1 0.00263
(0.0114)
basicness=2 × NoveltyCat=2 -0.269∗∗∗
(0.0231)
Constant -6.937∗∗∗ -6.995∗∗∗ -7.001∗∗∗ -7.044∗∗∗ -7.067∗∗∗
(0.0240) (0.0241) (0.0240) (0.0241) (0.0246)
Field fe X X X X X
Year fe X X X X X
Observations 5473178 5473178 5473178 5473178 5473178
Pseudo R2 0.169 0.175 0.171 0.177 0.177
BIC 1987364 1972407 1982902 1969238 1969037
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.6: Results of regression modeling of technological impact. The dependent variables are based on patents assigned to US companies.
Intensity (NB) Time lag (OLS) Longevity (OLS) Scope (OLS)
(1) (2) (3) (4) (5) (6) (7) (8)
scientific citation (ln) 0.263∗∗∗ 0.263∗∗∗ -0.264∗∗∗ -0.270∗∗∗ 0.333∗∗∗ 0.334∗∗∗ 0.0911∗∗∗ 0.0947∗∗∗
(0.00215) (0.00216) (0.00875) (0.00875) (0.00446) (0.00447) (0.00239) (0.00239)
Impact Factor 0.00790∗∗∗ 0.00764∗∗∗ -0.0360∗∗∗ -0.0344∗∗∗ 0.00562∗∗∗ 0.00524∗∗∗ 0.0136∗∗∗ 0.0129∗∗∗
(0.000701) (0.000701) (0.00265) (0.00265) (0.00135) (0.00135) (0.000716) (0.000715)
# MeSH -0.00670∗∗∗ -0.00832∗∗∗ -0.00338 0.00887∗∗∗ -0.00866∗∗∗ -0.0111∗∗∗ 0.00394∗∗∗ 0.0000832
(0.000581) (0.000624) (0.00225) (0.00240) (0.00115) (0.00123) (0.000607) (0.000648)
# ref (ln) -0.176∗∗∗ -0.175∗∗∗ 0.104∗∗∗ 0.146∗∗∗ -0.146∗∗∗ -0.151∗∗∗ 0.0309∗∗∗ 0.00951∗
(0.00409) (0.00414) (0.0153) (0.0155) (0.00782) (0.00793) (0.00414) (0.00419)
# author (ln) 0.0869∗∗∗ 0.0853∗∗∗ -0.416∗∗∗ -0.407∗∗∗ 0.116∗∗∗ 0.114∗∗∗ 0.0268∗∗∗ 0.0223∗∗∗
(0.00450) (0.00452) (0.0177) (0.0178) (0.00904) (0.00909) (0.00478) (0.00480)
basicness=1 0.0308∗∗∗ -0.703∗∗∗ 0.114∗∗∗ 0.333∗∗∗
(0.00873) (0.0328) (0.0168) (0.00885)
basicness=2 0.0180∗ -0.578∗∗∗ 0.0942∗∗∗ 0.267∗∗∗
(0.00833) (0.0316) (0.0161) (0.00853)
NoveltyCat=1 0.0374∗∗∗ -0.202∗∗∗ 0.0462∗∗∗ 0.0375∗∗∗
(0.00572) (0.0220) (0.0112) (0.00594)
NoveltyCat=2 0.159∗∗∗ -0.523∗∗∗ 0.193∗∗∗ 0.105∗∗∗
(0.0103) (0.0394) (0.0201) (0.0106)
patent citation (ln) 1.453∗∗∗ 1.451∗∗∗
(0.00268) (0.00268)
Constant -0.124∗∗∗ -0.145∗∗∗ 18.78∗∗∗ 18.94∗∗∗ -0.0448 -0.0845 0.393∗∗∗ 0.343∗∗∗
(0.0302) (0.0303) (0.116) (0.116) (0.0592) (0.0593) (0.0313) (0.0313)
lnalpha 1.060∗∗∗ 1.059∗∗∗
(0.00260) (0.00260)
Field fe X X X X X X X X
Year fe X X X X X X X X
Observations 615981 615981 311291 311291 311291 311291 311291 311291
(Pseudo) R2 0.0173 0.0175 0.192 0.194 0.0390 0.0395 0.536 0.538
BIC 2192905 2192700 1897077 1896428 1478400 1478305 1082106 1080576
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.7: Results of regression modeling of number of patent citations. The variance inflation factor statistics are
about 2, indicating no multicollinearity among the independent variables.
log10(patent citation) (OLS) Top 5% (logit) Top 10% (logit)
(1) (2) (3) (4) (5) (6)
scientific citation (ln) 0.0861∗∗∗ 0.0866∗∗∗ 0.732∗∗∗ 0.734∗∗∗ 0.595∗∗∗ 0.599∗∗∗
(0.000496) (0.000496) (0.00614) (0.00616) (0.00450) (0.00452)
Impact Factor 0.00495∗∗∗ 0.00482∗∗∗ 0.00951∗∗∗ 0.00904∗∗∗ 0.00955∗∗∗ 0.00891∗∗∗
(0.000152) (0.000152) (0.00126) (0.00127) (0.00101) (0.00102)
# MeSH 0.0000660 -0.000825∗∗∗ -0.00535∗∗∗ -0.0101∗∗∗ -0.00229∗ -0.00691∗∗∗
(0.000125) (0.000133) (0.00141) (0.00151) (0.00103) (0.00111)
# ref (ln) -0.0286∗∗∗ -0.0317∗∗∗ -0.279∗∗∗ -0.294∗∗∗ -0.201∗∗∗ -0.219∗∗∗
(0.000855) (0.000866) (0.0103) (0.0104) (0.00755) (0.00763)
# author (ln) 0.0298∗∗∗ 0.0291∗∗∗ 0.213∗∗∗ 0.207∗∗∗ 0.192∗∗∗ 0.190∗∗∗
(0.000985) (0.000990) (0.0114) (0.0115) (0.00839) (0.00847)
basicness=1 0.0551∗∗∗ 0.336∗∗∗ 0.344∗∗∗
(0.00181) (0.0238) (0.0169)
basicness=2 0.0423∗∗∗ 0.252∗∗∗ 0.286∗∗∗
(0.00175) (0.0234) (0.0167)
NoveltyCat=1 0.0130∗∗∗ 0.0690∗∗∗ 0.0703∗∗∗
(0.00120) (0.0148) (0.0106)
NoveltyCat=2 0.0437∗∗∗ 0.282∗∗∗ 0.241∗∗∗
(0.00221) (0.0244) (0.0181)
Constant -0.0184∗∗ -0.0316∗∗∗ -6.219∗∗∗ -6.303∗∗∗ -4.805∗∗∗ -4.903∗∗∗
(0.00646) (0.00647) (0.0820) (0.0824) (0.0584) (0.0588)
Field fe X X X X X X
Field fe X X X X X X
Observations 615981 615981 615126 615126 615981 615981
(Pseudo) R2 0.104 0.106 0.112 0.114 0.0887 0.0902
BIC 602360 601013 227991 227691 382928 382352
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.8: Logit regression of direct patent citation. Papers with multiple SC are assigned to the one most presented
in their reference list.
(1) (2) (3) (4) (5)
scientific citation (ln) 0.758∗∗∗ 0.775∗∗∗ 0.758∗∗∗ 0.774∗∗∗ 0.774∗∗∗
(0.00199) (0.00201) (0.00199) (0.00201) (0.00201)
Impact Factor 0.0375∗∗∗ 0.0318∗∗∗ 0.0372∗∗∗ 0.0319∗∗∗ 0.0318∗∗∗
(0.000767) (0.000763) (0.000768) (0.000765) (0.000765)
# MeSH 0.0133∗∗∗ 0.00755∗∗∗ 0.00427∗∗∗ 0.0000976 0.000328
(0.000471) (0.000476) (0.000499) (0.000504) (0.000505)
# ref (ln) 0.0233∗∗∗ -0.0397∗∗∗ 0.0271∗∗∗ -0.0333∗∗∗ -0.0332∗∗∗
(0.00306) (0.00310) (0.00307) (0.00311) (0.00311)
# author (ln) 0.225∗∗∗ 0.224∗∗∗ 0.224∗∗∗ 0.221∗∗∗ 0.221∗∗∗
(0.00367) (0.00372) (0.00368) (0.00373) (0.00373)
basicness=1 0.877∗∗∗ 0.846∗∗∗ 0.904∗∗∗
(0.00628) (0.00630) (0.00952)
basicness=2 0.666∗∗∗ 0.631∗∗∗ 0.637∗∗∗
(0.00634) (0.00636) (0.00881)
NoveltyCat=1 0.248∗∗∗ 0.207∗∗∗ 0.216∗∗∗
(0.00428) (0.00431) (0.00864)
NoveltyCat=2 0.506∗∗∗ 0.437∗∗∗ 0.665∗∗∗
(0.00822) (0.00826) (0.0184)
basicness=1 × NoveltyCat=1 -0.0562∗∗∗
(0.0115)
basicness=1 × NoveltyCat=2 -0.388∗∗∗
(0.0241)
basicness=2 × NoveltyCat=1 0.00832
(0.0103)
basicness=2 × NoveltyCat=2 -0.221∗∗∗
(0.0217)
Constant -6.527∗∗∗ -6.588∗∗∗ -6.591∗∗∗ -6.637∗∗∗ -6.658∗∗∗
(0.0206) (0.0207) (0.0207) (0.0208) (0.0213)
Field fe X X X X X
Year fe X X X X X
Observations 3660897 3660897 3660897 3660897 3660897
Pseudo R2 0.215 0.222 0.217 0.224 0.224
BIC 2022628 2002712 2017310 1998936 1998722
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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Table A.9: Results of regression modeling of technological impact. Papers with multiple SC are assigned to the one most presented in their reference list.
Intensity (NB) Time lag (OLS) Longevity (OLS) Scope (OLS)
(1) (2) (3) (4) (5) (6) (7) (8)
scientific citation (ln) 0.290∗∗∗ 0.291∗∗∗ -0.399∗∗∗ -0.405∗∗∗ 0.465∗∗∗ 0.467∗∗∗ 0.110∗∗∗ 0.114∗∗∗
(0.00152) (0.00152) (0.00773) (0.00774) (0.00443) (0.00444) (0.00222) (0.00222)
Impact Factor 0.00978∗∗∗ 0.00939∗∗∗ -0.0491∗∗∗ -0.0475∗∗∗ 0.00979∗∗∗ 0.00920∗∗∗ 0.0190∗∗∗ 0.0184∗∗∗
(0.000503) (0.000503) (0.00252) (0.00252) (0.00145) (0.00145) (0.000706) (0.000705)
# MeSH -0.00476∗∗∗ -0.00697∗∗∗ -0.00823∗∗∗ 0.00671∗∗ -0.00451∗∗∗ -0.00857∗∗∗ 0.00420∗∗∗ 0.000859
(0.000403) (0.000431) (0.00194) (0.00207) (0.00111) (0.00119) (0.000542) (0.000577)
# ref (ln) -0.126∗∗∗ -0.133∗∗∗ 0.140∗∗∗ 0.181∗∗∗ -0.161∗∗∗ -0.174∗∗∗ 0.0167∗∗∗ -0.00124
(0.00294) (0.00298) (0.0138) (0.0139) (0.00789) (0.00799) (0.00385) (0.00390)
# author (ln) 0.0667∗∗∗ 0.0630∗∗∗ -0.377∗∗∗ -0.359∗∗∗ 0.148∗∗∗ 0.142∗∗∗ 0.0362∗∗∗ 0.0306∗∗∗
(0.00313) (0.00315) (0.0153) (0.0154) (0.00877) (0.00881) (0.00428) (0.00429)
basicness=1 0.150∗∗∗ -0.783∗∗∗ 0.258∗∗∗ 0.309∗∗∗
(0.00601) (0.0279) (0.0160) (0.00780)
basicness=2 0.114∗∗∗ -0.541∗∗∗ 0.178∗∗∗ 0.222∗∗∗
(0.00585) (0.0274) (0.0157) (0.00765)
NoveltyCat=1 0.0295∗∗∗ -0.234∗∗∗ 0.0540∗∗∗ 0.0228∗∗∗
(0.00393) (0.0186) (0.0107) (0.00520)
NoveltyCat=2 0.136∗∗∗ -0.505∗∗∗ 0.206∗∗∗ 0.0972∗∗∗
(0.00709) (0.0341) (0.0196) (0.00953)
patent citation (ln) 1.603∗∗∗ 1.599∗∗∗
(0.00238) (0.00237)
Constant 0.231∗∗∗ 0.201∗∗∗ 18.30∗∗∗ 18.44∗∗∗ -0.583∗∗∗ -0.632∗∗∗ 0.339∗∗∗ 0.300∗∗∗
(0.0197) (0.0197) (0.0931) (0.0932) (0.0534) (0.0535) (0.0260) (0.0260)
lnalpha -0.189∗∗∗ -0.191∗∗∗
(0.00255) (0.00255)
Field fe X X X X X X X X
Year fe X X X X X X X X
Observations 411276 411276 411276 411276 411276 411276 411276 411276
(Pseudo) R2 0.0425 0.043 0.183 0.185 0.0576 0.0585 0.5973 0.5990
BIC 2090939 2089966 2488456 2487379 2030866 2030525 1440455 1438782
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
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